IL21 and hereditary clear cell renal cell carcinoma: Lastly, IL-21 is currently used in phase I and II clinical trials in renal cell carcinoma, melanoma and non-Hodgkin's lymphoma with an overall good safety profile and encouraging single agent activity [49], [63], [64], [65].